NEW YORK – Legendal Corporation, a leader in customized genetic medicine, biomaterials, and artificial intelligence, and Nanotronics, developer of advanced intelligent inspection systems and production devices for adaptive manufacturing, today announced a partnership agreement to commercialize, develop and provide next-generation gene therapy, peptide materials, nanomaterials, and characterization technologies. biological.
The two companies will collaborate to implement future modular fabrication laboratories and design inspection devices in the process of developing nanomedicine and related nanomaterials. Legendal’s new headquarters will be in the Brooklyn Navy Yard Industrial Park to ensure a coherent system, efficient collaboration, and creation of new potential products and lab infrastructure.
“The Nanotronics-Legendall partnership cements New York City’s position as a hub for life sciences and advanced manufacturing, strengthening the city-wide ecosystem of large corporations, particularly in Brooklyn,” said Lynsey Green, president and CEO of Brooklyn Navy Yard. This will enable companies to create new products at the forefront of life-improving therapies, and will also enable Nanotronics to continue building and investing in the local talent pools in New York City that support its growth and innovation.This combination of accomplishments embodies many of the principles of equitable and inclusive economic development, and is thus a win-win situation. Great for New York City and the Brooklyn Navy Yard.”
The two companies will collaborate to create the next generation of nanomaterials and build comprehensive capabilities to design, characterize, synthesize and support multiple therapeutic initiatives, including applications for rare diseases, hematology, infectious diseases, and biodefense. Legendal has proven effective drug delivery to bone marrow, immune cells and rare blood cell populations, as well as over 99 percent inhibition of the virus that causes COVID-19 using its innovative peptide and nanoparticle-based drug delivery technologies.
“With this partnership, our goal is to accelerate the scaling up and production of the next generation of drug delivery technologies for cells, tissues and synthetic peptides at the highest possible throughput, while accelerating the transitional development of precision therapies that “It is much needed. Achieving this goal will allow gene therapy to be delivered precisely where it is needed and without the problems we see with virus delivery systems. We are confident that this strategic partnership promises to reach new heights in medicine, biotherapeutics and manufacturing.”
In its quest to accelerate Ligandal’s treatment programs and demonstrate the safety and efficacy of clinical applications, the company is continuing its development path to find treatments for rare hematological genetic diseases, immuno-oncology and biodefense applications, including further trials of the SARS-CoV-2 virus. This is done in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institutes of Health (NIH).
“The opportunities and synergies gained here will range from preventing and treating genetic diseases, correcting general metabolic and degenerative disorders, increasing and enhancing “A stronger immune response against diseases like COVID and other emerging infectious diseases and cancers. This platform and partnership helps bridge the gaps between long-term health inequalities and the current generation of treatments.”
LEGENDAL has demonstrated rapid predictive capabilities for the production of peptides to mimic biological reactions, driven by an AI-based approach to simulating, designing, and synthesising cell-specific targeting techniques for implementation, review, and subsequent phases of gene therapy.
Dr Matthew Putman, CEO and co-founder of Nanotronics, said: “We are extremely proud to collaborate with Andre and his team to develop personalized genomic medicine and will deploy our engineers as quickly as possible to improve the manufacturing process of their drug delivery technologies and accompany them every step of the way. using our AIPC platform.
About Legendal The Legendal
Corporation develops next-generation precision genetic nanomedicine and drug delivery technologies for gene editing, gene therapy, regenerative medicine, and biotechnology applications for epidemic defense. The company uses computational biology, machine learning and artificial intelligence with a new platform to deliver drugs to cells, tissues and the next generation of nanomaterials. Legendal also develops peptide-based technologies for gene therapy, gene editing, regenerative medicine, immunotherapy and advanced anti-vaccine technologies, and uses computational biology approaches to come up with predictive methods for delivering and modifying treatments for various conditions.
Legendal is focusing its efforts on blood gene editing, as well as creating a COVID-19 mitigation platform, such as the SARS-Block platform, which is designed as an early and preventative treatment against the virus that causes COVID-19. Legendal has several programs in the discovery stage to treat rare diseases and cancers using its new peptide-based nanomaterials platform.
About Nanotronics Nanotronics
is a manufacturer of advanced machinery and information. It helps clients in the public, private and not-for-profit sectors solve unique inspection and process control challenges for precision manufacturing. As a leading developer of automated optical inspection tools for the semiconductor industry, Nanotronics uses hardware and software to provide high-throughput, high-throughput imaging systems.
Spread in fifteen countries and not allocated to a single sector, Nanotronics collaborates with cutting-edge companies around the world, from aerospace to electronics and healthcare, to increase revenues, reduce carbon footprint and waste, reduce costs, accelerate design, and eliminate waste. Painstaking manual inspections.
For more information, please visit the following two links: www.nanotronics.co and www.ligandal.com.
You can view the original version of this press release on businesswire.com at
https://www.businesswire.com/news/home/20220622005542/en/
The original language text of this statement is the official approved version. As for the translation, it is provided for assistance only, and reference must be made to the original language text, which is the only version with legal effect.
* Source: “AETOSWire”
